Sana Biotechnology, Inc. (SANA)

9,15 +0,55 (+6,40 %) À partir de 02:50PM EDT. Marché ouvert.

Sana Biotechnology, Inc.

188 East Blaine Street
Suite 400
Seattle, WA 98102
United States
206 701 7914
https://www.sana.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 328

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Steven D. Harr M.D.	President, CEO & Director	1,04M	S.O.	1970
Mr. Nathan Hardy M.B.A.	Executive VP & CFO	653,04k	S.O.	1976
Mr. Snehal Patel	Senior VP & Chief Technical Officer	S.O.	S.O.	S.O.
Mr. Bernard J. Cassidy J.D.	Executive VP, General Counsel & Corporate Secretary	491,39k	S.O.	1955
Ms. Robin Andrulevich	Executive VP & Chief People Officer	S.O.	S.O.	1966
Dr. Edward Rebar Ph.D.	Head of Cell Engineering	S.O.	S.O.	1968
Mr. Paul Brunetta M.D.	Senior VP and Head of Clinical & Translational Science	S.O.	S.O.	S.O.
Mr. Christian Hordo M.B.A.	Executive VP & Chief Business Officer	485,03k	S.O.	1983
Dr. Sonja Schrepfer M.D., Ph.D.	Senior VP & Head of Hypoimmune Platform	S.O.	S.O.	1975
Dr. Terry Fry M.D.	Senior VP & Head of T Cell Therapeutics	S.O.	S.O.	1967

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Sana Biotechnology, Inc. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 2; Société : 7; Droits des actionnaires : 8; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.